Navigation Links
The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxter's Cell-Based Pandemic, Avian Flu Vaccine
Date:6/11/2008

. "This is an immunogenic vaccine without the need for an adjuvant to boost the immune response."

About CELVAPAN

CELVAPAN is manufactured in a cell culture-based system in Bohumil, Czech Republic, at one of the largest cell culture vaccine production facilities in the world. Vero cell technology uses a well-established cell line originally derived from African green monkey kidneys in 1962. A continuous cell line has been derived from these cells so that an unlimited supply of cells is available without the requirement of generating additional cells from animals.

Baxter's candidate avian flu vaccine is derived from the H5N1 strain A/Vietnam/1203/2004. Its antigen composition and structure are identical to the actual virus circulating in nature without the need to enhance an immune response by including adjuvants, additives that may cause side effects. In this Phase I/II study, CELVAPAN induced an immune response that is similar to the body's defense against a natural virus infection. Earlier this year CELVAPAN was accepted for licensure review by the Committee for Medicinal Products for Human Use within the European Medicines Agency, making it the first cell culture-based pandemic influenza vaccine to be reviewed by the regulatory authority. The U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is also conducting a trial with Baxter's CELVAPAN in the United States.

Phase I/II Clinical Trial Results

The randomized Phase I/II study enrolled 284 subjects in Austria and Singapore (ages 18-45) and met its immunogenicity and safety endpoints. The study mainly investigated the ability of the vaccine to induce substantial levels of cross-immunity against divergent H5N1 strains.

The trial tested four different antigen concentrations ranging from 3.75 micrograms to 30 micrograms; 7.5 micrograms and 15 micrograms formulations were studied with and without adjuvant (additive).
'/>"/>

SOURCE Baxter International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Results from Study Evaluating PROCRIT(R) in Intensive Care Unit Patients Published in New England Journal of Medicine
2. Vaccine Study in New England Journal of Medicine Wrong in Concluding Mercury Exposures are Harmless, States SafeMinds
3. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
4. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
5. New England Journal of Medicine Study Shows ERBITUX(R) Improves Survival in Advanced Colorectal Cancer
6. Berkery Noyes Represented The Thomson Corporation in the Sale of CenterWatch and New England Institutional Review Board to Jobson Medical Information
7. New England Journal of Medicine Publishes Results From a RELISTOR Phase 3 Clinical Study
8. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
9. Adlyfe Study on the Detection of Misfolded Proteins Published in the Journal Transfusion
10. Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
11. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... 1, 2015 Ardelyx, Inc. (NASDAQ: ... gastrointestinal and cardio-renal diseases, today announced that Sanofi ... and license agreement for Ardelyx,s portfolio of NaP2b ... payment associated with termination and the return of ... Sanofi entered into an option and license agreement ...
(Date:9/1/2015)... 1, 2015 Emerus Holdings, a national ... inpatient and diagnostic care in partnership with leading ... definitive agreement to receive a strategic investment from ... leading health care investment firm. Emerus ... acute episodic and ambulatory clinical services to communities ...
(Date:9/1/2015)... --  Alpha Imaging LLC , a leading distributor of advanced medical ... that they have been awarded exclusive rights to represent the complete ... new territory supplements Alpha Imaging,s existing Shimadzu sales and service responsibilities ... , Indiana , Pennsylvania , ... West Virginia , Delaware and ...
Breaking Medicine Technology:Ardelyx Regains NaP2b Program from Sanofi 2Ardelyx Regains NaP2b Program from Sanofi 3Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 2Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 3Alpha Imaging Expands Shimadzu Territory 2
... at Brigham and Women,s,Hospital found that patients taking cannabinoid ... were unrelated to relief from their pain,symptoms. Results ... the addictive,potential of this class of pain medicine, were ... Annual Meeting. , In the ...
... The Netherlands, January 28 ,Amsterdam Molecular Therapeutics ... of,human gene therapy, announced today during the ... showing that one treatment of its lead ... and clinically important,lowering of the incidence of ...
Cached Medicine Technology:Study of Cannabinoid Medicine for Pain Found Patients Got 'High,' but Effects Not Related to Pain Relief 2AMT: Glybera(R) Lowers Pancreatitis Incidence Significantly 2AMT: Glybera(R) Lowers Pancreatitis Incidence Significantly 3
(Date:9/1/2015)... London, UK (PRWEB) , ... ... ... are constantly seeking better therapeutic options to efficiently cure and prevent different ... classes. Different cancers have different pathophysiological properties due to which distinctive approach ...
(Date:9/1/2015)... ... 01, 2015 , ... Splashtop Inc. , the worldwide ... , a solution optimized for MSPs and IT professionals looking for a cost ... inadequate customer services of existing remote support solution, many MSPs and ITs have ...
(Date:9/1/2015)... ... September 01, 2015 , ... Plaza OBGYN in ... MonaLisa Touch® , an innovative vaginal health laser procedure that prevents and resolves ... treatment for atrophic vaginitis, a condition that causes vaginal dryness, pelvic discomfort, painful ...
(Date:9/1/2015)... ... September 01, 2015 , ... The Jerry Segal Classic to ... Club and Green Valley Country Club in Lafayette Hill, PA. Over the past 26 ... $13.5 million for programs and services designed to support patients and their families during ...
(Date:9/1/2015)... ... September 01, 2015 , ... Discovia, a leading global provider ... it has hired Scott Sanderson, an experienced business development professional and former NFL ... responsible for establishing and managing new client relationships in the Southeast U.S. ...
Breaking Medicine News(10 mins):Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 2Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 3Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 2Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 3Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 4Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 2Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 3Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 2Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 3Health News:Former NFL Standout Scott Sanderson Joins eDiscovery Leader Discovia 2
... at Johns Hopkins and the University of Michigan have developed ... ,The findings will be published in the ... of Sciences. The study has implications for treating people who ... in which nerves are wrenched from the spinal cord. The ...
... Body mass index (BMI), which is the ratio of height and ... patients. A lower BMI is associated with a lesser weight// and ... with obesity and its allied health risks. , ... that measure how the weight is distributed on the body are ...
... charity organization it was shocking to find that about three-quarters ... of chronic obstructive pulmonary disease (COPD). , The ... disease. COPD is UK’s fifth-biggest killer disease as it affects ... deaths a year. The medical charity organization called the Developing ...
... Department of Health have admitted that some nursing homes do ... This does not concur with the existing legislation. ,Fine ... on more illegal charges was worrying. "It is absolutely disgraceful ... the income of a spouse of a long-stay public nursing ...
... Hospital, gauged the cost-benefit of shifting the responsibility of caring ... said that there was no major economic savings in such ... the driving force behind the idea of such a shift, ... 220 senior patients, recouping from illness, that there were not ...
... Medical education in Australia is getting caught in a number ... a wake up call. This coupled with dwindling// numbers of ... the field of healthcare education. ,Australian Medical Association president ... that parents and students will borrow, scrimp and save in ...
Cached Medicine News:Health News:Scientists Coax Nerve Fibers to Regrow After Spinal Cord Injury 2Health News:Scientists Coax Nerve Fibers to Regrow After Spinal Cord Injury 3Health News:Scientists Coax Nerve Fibers to Regrow After Spinal Cord Injury 4Health News:A high BMI may not determine obesity, researchers say 2
Used to negotiate tortuous vessels....
BiodivYsio stent with biocompatible coating (phosphorylcholine)...
... The CYPHER Sirolimus-eluting Coronary Stent ... drug, called "sirolimus", a controlled-release ... delivery platform. Upon placement, sirolimus ... and impedes the process of ...
PT wires combine the enhanced durability of a linear elastic nitinol distal core and a highly resilient polymer tip. This provides excellent access in difficult cases involving severe tortuosity, tig...
Medicine Products: